Vanda Pharmaceuticals secured FDA approval for Nereus to prevent motion sickness-induced vomiting in late December 2025. The company has already initiated ordering for its specialty pharmacy network and plans a phased roll-out across major cruise lines and travel retailers by Q2 2026. Management forecasts Nereus could reach peak annual sales of $150 million by 2028, based on conservative market uptake assumptions and a $50 wholesale acquisition cost per treatment course. Early distributor agreements cover more than 80% of U.S. cruise ship pharmacies, positioning Vanda to capture the travel‐related nausea segment swiftly.

In the third quarter of 2025, Vanda reported 24% year-over-year growth in Fanapt® sales, driven by expanded prescribing in community psychiatric settings. However, heightened R&D spending on late-stage trials and increased SG&A associated with building a U.S. commercial infrastructure resulted in a net loss of $22.6 million. Fanapt generated $68.4 million in revenue, up from $55.1 million in the prior-year quarter, underscoring steady traction in its schizophrenia franchise even as the company ramps resources for multiple product launches.

As of December 31, 2025, Vanda held $293.8 million in cash, cash equivalents, and marketable securities. The company reaffirmed its revenue guidance for full-year 2025 at $210–230 million, reflecting contributions from Fanapt, Hetlioz® for non-24 sleep disorder, and the early commercialization of Nereus. Free cash flow is projected to turn positive in H2 2026 as launch-related expenses normalize and topline growth accelerates. Vanda’s cash runway extends through 2028 under current spending plans, supporting multiple late-stage programs without the need for near-term equity financing.

Investors are focused on the anticipated PDUFA date for Bysanti®, Vanda’s oral therapy for chemotherapy-induced nausea, set for October 2026. Analysts estimate a blockbusters sales potential of $400 million annually if approved, given the lack of oral alternatives in this patient population. In addition, the company’s Phase III trial of VP-102 for molluscum contagiosum is expected to read out in Q3 2026, potentially opening a new dermatology franchise. Collectively, these catalysts underpin a bullish outlook, with shares offering upside as clinical milestones unfold in the coming 12 months.